Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.
Brief Summary: The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal osteoporotic women.


Options:
A: Inclusion Criteria:

* Ambulatory women,
* Caucasian, Oriental or Multiracial
* not previously diagnosed for osteoporosis.

Exclusion Criteria:

* Females of black descent and for the US african american are excluded because of the very low incidence of postmenopausal osteoporosis
* and having used oral or parenteral glucocorticoids (\>= 5 mg prednisone or equivalent per day) within 3 months of starting study drug or for more than one month within six months prior to study entry.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
B: Inclusion Criteria:

* Postmenopausal women with osteoporosis, as defined by low bone mineral density (BMD), i.e. anterior-posterior lumbar spine, total hip or femoral neck BMD ≥1.5 standard deviations below the average BMD for young, healthy, non-Hispanic, Caucasian women
* A minimum of 2 moderate or 1 severe vertebral fragility fractures (confirmed by central reader) were required

Exclusion Criteria:

* Increased risk of osteosarcoma
* History of unresolved skeletal diseases that affect bone metabolism
* History of atypical subtrochanteric or diaphyseal femoral fractures
* Abnormally high or low calcium levels
* Abnormally high parathyroid hormone (PTH) levels
* Severe vitamin D deficiency
* Abnormal thyroid function not corrected by therapy
* History of malignant neoplasms in the last 5 years
* Active liver disease, clinical jaundice
* Significant impairment of hepatic or renal function
* History of nephro- or urolithiasis
* Previous or planned kypho- or vertebroplasty
* Active or risk for osteonecrosis of the jaw
* Active or recent history of upper gastrointestinal disorders
* Unable to stand or sit in the upright position for at least 30 minutes
C: Inclusion Criteria:

* At least 4 years post-menopausal

Exclusion Criteria:

* Not currently taking estrogen replacement therapy or undergoing any treatment for osteoporosis
* Diagnosis of breast cancer
* Results of mammogram suggesting breast cancer
D: Inclusion Criteria:

* Female: 50 years of age or older
* \>5 years since last menses natural or surgical
* have lumbar spine or total hip BMD more that 2.5 SD below the young adult mean, or have lumbar spine or total hip BMD more than 2.0 SD below the young adult female mean value and also have at least one prevalent vertebral body fracture

Exclusion Criteria:

* history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia
* BMI \>32 kg/m
* use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone
* hypocalcemia or hypercalcemia of any cause
* markedly abnormal clinical laboratory measurements that are assessed as clinically significant by the investigator

Answer: A